Archives of Toxicology

, Volume 88, Issue 7, pp 1427–1437

Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes

  • Anna-Karin M. Sjogren
  • Maria Liljevald
  • Björn Glinghammar
  • Johanna Sagemark
  • Xue-Qing Li
  • Anna Jonebring
  • Ian Cotgreave
  • Gabriella Brolén
  • Tommy B. Andersson
Molecular Toxicology

DOI: 10.1007/s00204-014-1265-z

Cite this article as:
Sjogren, AK.M., Liljevald, M., Glinghammar, B. et al. Arch Toxicol (2014) 88: 1427. doi:10.1007/s00204-014-1265-z


Human-induced pluripotent stem cell-derived hepatocytes (hiPSC-Hep) hold great potential as an unlimited cell source for toxicity testing in drug discovery research. However, little is known about mechanisms of compound toxicity in hiPSC-Hep. In this study, modified mRNA was used to reprogram foreskin fibroblasts into hiPSC that were differentiated into hiPSC-Hep. The hiPSC-Hep expressed characteristic hepatic proteins and exhibited cytochrome P450 (CYP) enzyme activities. Next, the hiPSC-Hep, primary cryopreserved human hepatocytes (cryo-hHep) and the hepatic cell lines HepaRG and Huh7 were treated with staurosporine and acetaminophen, and the toxic responses were compared. In addition, the expression of genes regulating and executing apoptosis was analyzed in the different cell types. Staurosporine, an inducer of apoptosis, decreased ATP levels and activated caspases 3 and 7 in all cell types, but to less extent in Huh7. Furthermore, a hierarchical clustering and a principal component analysis (PCA) of the expression of apoptosis-associated genes separated cryo-hHep from the other cell types, while an enrichment analysis of apoptotic pathways identified hiPSC-Hep as more similar to cryo-hHep than the hepatic cell lines. Finally, acetaminophen induced apoptosis in hiPSC-Hep, HepaRG and Huh7, while the compound initiated a direct necrotic response in cryo-hHep. Our results indicate that for studying compounds initiating apoptosis directly hiPSC-Hep may be a good alternative to cryo-hHep. Furthermore, for compounds with more complex mechanisms of toxicity involving metabolic activation, such as acetaminophen, our data suggest that the cause of cell death depends on a balance between factors controlling death signals and the drug-metabolizing capacity.


Hepatotoxicity Drug-induced liver injury iPS cells HepaRG Acetaminophen Apoptosis 



Human-induced pluripotent stem cells


Human-induced pluripotent stem cell-derived hepatocytes


Cytochrome P450


Cryopreserved human hepatocytes


Principal component analysis


N-acetyl-p-benzoquinone imine


Periodic acid schiff


Liquid chromatography/mass spectrometry


Quantitative real-time PCR


Cycle of threshold




LC-/MS-radiochemical activity monitoring


Hepatocyte nuclear factor 4 alpha


Cytokeratin 18


Alpha-1 antitrypsin




Pregnane X receptor



Supplementary material

204_2014_1265_MOESM1_ESM.pdf (67.8 mb)
Supplementary material 1 (PDF 69395 kb)
204_2014_1265_MOESM2_ESM.pdf (159 kb)
Supplementary material 2 (PDF 158 kb)
204_2014_1265_MOESM3_ESM.pdf (224 kb)
Supplementary material 3 (PDF 224 kb)
204_2014_1265_MOESM4_ESM.pdf (215 kb)
Supplementary material 4 (PDF 214 kb)
204_2014_1265_MOESM5_ESM.pdf (191 kb)
Supplementary material 5 (PDF 190 kb)
204_2014_1265_MOESM6_ESM.docx (40 kb)
Supplementary material 6 (DOCX 40 kb)
204_2014_1265_MOESM7_ESM.pdf (214 kb)
Supplementary material 7 (PDF 213 kb)
204_2014_1265_MOESM8_ESM.pdf (314 kb)
Supplementary material 8 (PDF 314 kb)
204_2014_1265_MOESM9_ESM.pdf (176 kb)
Supplementary material 9 (PDF 175 kb)
204_2014_1265_MOESM10_ESM.pdf (470 kb)
Supplementary material 10 (PDF 470 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Anna-Karin M. Sjogren
    • 1
  • Maria Liljevald
    • 2
  • Björn Glinghammar
    • 2
  • Johanna Sagemark
    • 2
  • Xue-Qing Li
    • 1
  • Anna Jonebring
    • 3
  • Ian Cotgreave
    • 4
  • Gabriella Brolén
    • 3
  • Tommy B. Andersson
    • 1
    • 5
  1. 1.Cardiovascular and Metabolic Diseases Innovative Medicines, DMPKAstraZeneca R&DMölndalSweden
  2. 2.Drug Safety and Metabolism, Discovery SafetyAstraZeneca R&DMölndalSweden
  3. 3.Discovery Sciences, Reagents and Assay DevelopmentAstraZeneca R&DMölndalSweden
  4. 4.Unit of Biochemical Toxicology, Institute of Environmental MedicineKarolinska InstituteStockholmSweden
  5. 5.Section of Pharmacogenetics, Department of Physiology and PharmacologyKarolinska InstituteStockholmSweden

Personalised recommendations